The interplay of inflammation and cardiovascular disease in systemic lupus erythematosus

Arthritis Research and Therapy

Volumn 13, Issue 1, 2011, Pages

  Kahlenberg, J Michelle ^a   Kaplan, Mariana J ^a  

^a UNIVERSITY OF MICHIGAN   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AZATHIOPRINE; CORTICOSTEROID; CYCLOPHOSPHAMIDE; INTERFERON; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PHOSPHOLIPID ANTIBODY; STATIN;

ATHEROSCLEROSIS; BLOOD VESSEL INJURY; CARDIOVASCULAR DISEASE; CLINICAL EXAMINATION; DRUG MEGADOSE; ENDOTHELIUM INJURY; HUMAN; IMMUNE DYSREGULATION; INFLAMMATION; LOW DRUG DOSE; PATHOGENESIS; REVIEW; SYSTEMIC LUPUS ERYTHEMATOSUS; ANIMAL; IMMUNOLOGY; PATHOLOGY;

ANIMALS; CARDIOVASCULAR DISEASES; HUMANS; INFLAMMATION; LUPUS ERYTHEMATOSUS, SYSTEMIC;

EID: 80052720931     PISSN: 14786354     EISSN: 14786362     Source Type: Journal    
DOI: 10.1186/ar3264     Document Type: Review

References (103)

1. Urowitz MB, Bookman AA, Koehler BE, Gordon DA, Smythe HA, Ogryzlo MA. The bimodal mortality pattern of systemic lupus erythematosus. Am J Med 1976, 60:221-225. 10.1016/0002-9343(76)90431-9, 1251849.
2. Manzi S, Meilahn EN, Rairie JE, Conte CG, Medsger TA, Jansen-McWilliams L, D'Agostino RB, Kuller LH. Age-specific incidence rates of myocardial infarction and angina in women with systemic lupus erythematosus: comparison with the Framingham Study. Am J Epidemiol 1997, 145:408-415.
3. Hak AE, Karlson EW, Feskanich D, Stampfer MJ, Costenbader KH. Systemic lupus erythematosus and the risk of cardiovascular disease: Results from the nurses' health study. Arthritis Rheum 2009, 61:1396-1402. 10.1002/art.24537, 2909444, 19790130.
4. Esdaile JM, Abrahamowicz M, Grodzicky T, Li Y, Panaritis C, du Berger R, Côte R, Grover SA, Fortin PR, Clarke AE, Senécal JL. Traditional Framingham risk factors fail to fully account for accelerated atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2001, 44:2331-2337. 10.1002/1529-0131(200110)44:10<2331::AID-ART395>3.0.CO;2-I, 11665973.
5. Roman MJ, Crow MK, Lockshin MD, Devereux RB, Paget SA, Sammaritano L, Levine DM, Davis A, Salmon JE. Rate and determinants of progression of atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2007, 56:3412-3419. 10.1002/art.22924, 17907140.
6. Rajagopalan S, Somers EC, Brook RD, Kehrer C, Pfenninger D, Lewis E, Chakrabarti A, Richardson BC, Shelden E, McCune WJ, Kaplan MJ. Endothelial cell apoptosis in systemic lupus erythematosus: a common pathway for abnormal vascular function and thrombosis propensity. Blood 2004, 103:3677-3683. 10.1182/blood-2003-09-3198, 14726373.
7. El-Magadmi M, Bodill H, Ahmad Y, Durrington PN, Mackness M, Walker M, Bernstein RM, Bruce IN. Systemic lupus erythematosus: an independent risk factor for endothelial dysfunction in women. Circulation 2004, 110:399-404. 10.1161/01.CIR.0000136807.78534.50, 15262847.
8. Manzi S, Selzer F, Sutton-Tyrrell K, Fitzgerald SG, Rairie JE, Tracy RP, Kuller LH. Prevalence and risk factors of carotid plaque in women with systemic lupus erythematosus. Arthritis Rheum 1999, 42:51-60. 10.1002/1529-0131(199901)42:1<51::AID-ANR7>3.0.CO;2-D, 9920014.
9. Roldan C, Joson J, Sharrar J, Qualls C, Sibbitt W. Premature aortic atherosclerosis in systemic lupus erythematosus: a controlled transesophageal echocardiographic study. J Rheumatol 2010, 37:71-78. 10.3899/jrheum.090665, 19955049.
10. Kiani AN, Vogel-Claussen J, Magder LS, Petri M. Noncalcified coronary plaque in systemic lupus erythematosus. J Rheumatol 2010, 37:579-584. 10.3899/jrheum.090824, 20110529.
11. Recio-Mayoral A, Mason JC, Kaski JC, Rubens MB, Harari OA, Camici PG. Chronic inflammation and coronary microvascular dysfunction in patients without risk factors for coronary artery disease. Eur Heart J 2009, 30:1837-1843. 10.1093/eurheartj/ehp205, 19502228.
12. Pieretti J, Roman MJ, Devereux RB, Lockshin MD, Crow MK, Paget SA, Schwartz JE, Sammaritano L, Levine DM, Salmon JE. Systemic lupus erythematosus predicts increased left ventricular mass. Circulation 2007, 116:419-426. 10.1161/CIRCULATIONAHA.106.673319, 17620509.
13. Hansson GK. Inflammation, atherosclerosis, and coronary artery disease. N Engl J Med 2005, 352:1685-1695. 10.1056/NEJMra043430, 15843671.
14. Duewell P, Kono H, Rayner KJ, Sirois CM, Vladimer G, Bauernfeind FG, Abela GS, Franchi L, Nuñez G, Schnurr M, Espevik T, Lien E, Fitzgerald KA, Rock KL, Moore KJ, Wright SD, Hornung V, Latz E. NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals. Nature 2010, 464:1357-1361. 10.1038/nature08938, 2946640, 20428172.
15. Lindner V, Fingerle J, Reidy MA. Mouse model of arterial injury. Circ Res 1993, 73:792-796.
16. Mallat Z, Benamer H, Hugel B, Benessiano J, Steg PG, Freyssinet JM, Tedgui A. Elevated levels of shed membrane microparticles with procoagulant potential in the peripheral circulating blood of patients with acute coronary syndromes. Circulation 2000, 101:841-843.
17. Chironi GN, Boulanger CM, Simon A, Dignat-George F, Freyssinet JM, Tedgui A. Endothelial microparticles in diseases. Cell Tissue Res 2009, 335:143-151. 10.1007/s00441-008-0710-9, 18989704.
18. Briasoulis A, Tousoulis D, Antoniades C, Stefanadis C, Papageorgiou N. The role of endothelial progenitor cells in vascular repair after arterial injury and atherosclerotic plaque development. Cardiovasc Ther 2010,
19. Schmidt-Lucke C, Rössig L, Fichtlscherer S, Vasa M, Britten M, Kämper U, Dimmeler S, Zeiher AM. Reduced number of circulating endothelial progenitor cells predicts future cardiovascular events: proof of concept for the clinical importance of endogenous vascular repair. Circulation 2005, 111:2981-2987. 10.1161/CIRCULATIONAHA.104.504340, 15927972.
20. George J, Herz I, Goldstein E, Abashidze S, Deutch V, Finkelstein A, Michowitz Y, Miller H, Keren G. Number and adhesive properties of circulating endothelial progenitor cells in patients with in-stent restenosis. Arterioscler Thromb Vasc Biol 2003, 23:e57-60. 10.1161/01.ATV.0000107029.65274.db, 14615392.
21. Vasa M, Fichtlscherer S, Aicher A, Adler K, Urbich C, Martin H, Zeiher AM, Dimmeler S. Number and migratory activity of circulating endothelial progenitor cells inversely correlate with risk factors for coronary artery disease. Circ Res 2001, 89:E1-E7. 10.1161/hh1301.093953, 11440984.
22. MacEneaney OJ, Kushner EJ, Westby CM, Cech JN, Greiner JJ, Stauffer BL, DeSouza CA. Endothelial progenitor cell function, apoptosis, and telomere length in overweight/obese humans. Obesity 2010, 18:1677-1682. 10.1038/oby.2009.494, 20057362.
23. Zhang Y, Herbert BS, Rajashekhar G, Ingram DA, Yoder MC, Clauss M, Rehman J. Premature senescence of highly proliferative endothelial progenitor cells is induced by tumor necrosis factor-alpha via the p38 mitogen-activated protein kinase pathway. FASEB J 2009, 23:1358-1365. 10.1096/fj.08-110296, 2669419, 19124561.
24. Brunetti ND, Munno I, Pellegrino PL, Ruggero V, Correale M, De Gennaro L, Cuculo A, Campanale EG, Di Biase M. Inflammatory cytokines imbalance in the very early phase of acute coronary syndrome: correlations with angiographic findings and in-hospital events. Inflammation 2011, 34:58-66. 10.1007/s10753-010-9208-1, 20405189.
25. Reynolds HR, Buyon J, Kim M, Rivera TL, Izmirly P, Tunick P, Clancy RM. Association of plasma soluble E-selectin and adiponectin with carotid plaque in patients with systemic lupus erythematosus. Atherosclerosis 2010, 210:569-574. 10.1016/j.atherosclerosis.2009.12.007, 20044088.
26. Rho YH, Chung CP, Oeser A, Solus J, Raggi P, Gebretsadik T, Shintani A, Stein CM. Novel cardiovascular risk factors in premature coronary atherosclerosis associated with systemic lupus erythematosus. J Rheumatol 2008, 35:1789-1794. 2574747, 18634156.
27. Westerweel PE, Luijten RK, Hoefer IE, Koomans HA, Derksen RH, Verhaar MC. Haematopoietic and endothelial progenitor cells are deficient in quiescent systemic lupus erythematosus. Ann Rheum Dis 2007, 66:865-870. 10.1136/ard.2006.065631, 1955125, 17329307.
28. Denny MF, Thacker S, Mehta H, Somers EC, Dodick T, Barrat FJ, McCune WJ, Kaplan MJ. Interferon-alpha promotes abnormal vasculogenesis in lupus: a potential pathway for premature atherosclerosis. Blood 2007, 110:2907-2915. 10.1182/blood-2007-05-089086, 2018671, 17638846.
29. Baechler EC, Batliwalla FM, Karypis G, Gaffney PM, Ortmann WA, Espe KJ, Shark KB, Grande WJ, Hughes KM, Kapur V, Gregersen PK, Behrens TW. Interferon-inducible gene expression signature in peripheral blood cells of patients with severe lupus. Proc Natl Acad Sci USA 2003, 100:2610-2615. 10.1073/pnas.0337679100, 151388, 12604793.
30. Kim T, Kanayama Y, Negoro N, Okamura M, Takeda T, Inoue T. Serum levels of interferons in patients with systemic lupus erythematosus. Clin Exp Immunol 1987, 70:562-569. 1542177, 2449306.
31. Kariuki SN, Kirou KA, MacDermott EJ, Barillas-Arias L, Crow MK, Niewold TB. Cutting edge: autoimmune disease risk variant of STAT4 confers increased sensitivity to IFN-alpha in lupus patients in vivo. J Immunol 2009, 182:34-38. 2716754, 19109131.
32. Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ. The detrimental effects of IFN-α on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010, 185:4457-4469. 10.4049/jimmunol.1001782, 20805419.
33. Thacker SG, Duquaine D, Park J, Kaplan MJ. Lupus-prone New Zealand Black/New Zealand White F1 mice display endothelial dysfunction and abnormal phenotype and function of endothelial progenitor cells. Lupus 2010, 19:288-299. 10.1177/0961203309353773, 20068018.
34. Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, Butfiloski EJ, Sobel ES, Reeves WH, Segal MS. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007, 56:3759-3769. 10.1002/art.23035, 17968925.
35. Zhao W, Somers E, McCune WJ, Kaplan MJ. Type I Interferon signatures are associated with vascular risk and atherosclerosis in systemic lupus erythematosus. Arthritis Rheum 2009, 59:S582.
36. Thacker SG, Berthier CC, Mattinzoli D, Rastaldi MP, Kretzler M, Kaplan MJ. The detrimental effects of IFN-{alpha} on vasculogenesis in lupus are mediated by repression of IL-1 pathways: potential role in atherogenesis and renal vascular rarefaction. J Immunol 2010, 185:4457-4469. 10.4049/jimmunol.1001782, 20805419.
37. Denny MF, Yalavarthi S, Zhao W, Thacker SG, Anderson M, Sandy AR, McCune WJ, Kaplan MJ. A distinct subset of proinflammatory neutrophils isolated from patients with systemic lupus erythematosus induces vascular damage and synthesizes type I IFNs. J Immunol 2010, 184:3284-3297. 10.4049/jimmunol.0902199, 2929645, 20164424.
38. Hacbarth E, Kajdacsy-Balla A. Low density neutrophils in patients with systemic lupus erythematosus, rheumatoid arthritis, and acute rheumatic fever. Arthritis Rheum 1986, 29:1334-1342. 10.1002/art.1780291105, 2430586.
39. Bennett L, Palucka AK, Arce E, Cantrell V, Borvak J, Banchereau J, Pascual V. Interferon and granulopoiesis signatures in systemic lupus erythematosus blood. J Exp Med 2003, 197:711-723. 10.1084/jem.20021553, 2193846, 12642603.
40. Niessner A, Shin MS, Pryshchep O, Goronzy JJ, Chaikof EL, Weyand CM. Synergistic proinflammatory effects of the antiviral cytokine interferon-alpha and Toll-like receptor 4 ligands in the atherosclerotic plaque. Circulation 2007, 116:2043-2052. 10.1161/CIRCULATIONAHA.107.697789, 17938289.
41. Niessner A, Weyand CM. Dendritic cells in atherosclerotic disease. Clin Immunol 2010, 134:25-32. 10.1016/j.clim.2009.05.006, 2821659, 19520615.
42. Enocsson H, Sjöwall C, Skogh T, Eloranta ML, Rönnblom L, Wetterö J. Interferon-alpha mediates suppression of C-reactive protein: explanation for muted C-reactive protein response in lupus flares?. Arthritis Rheum 2009, 60:3755-3760. 10.1002/art.25042, 19950271.
43. Nikpour M, Gladman DD, Ibaez D, Urowitz MB. Variability and correlates of high sensitivity C-reactive protein in systemic lupus erythematosus. Lupus 2009, 18:966-973. 10.1177/0961203309105130, 19762397.
44. McMahon M, Hahn BH. Atherosclerosis and systemic lupus erythematosus - mechanistic basis of the association. Curr Opin Immunol 2007, 19:633-639. 10.1016/j.coi.2007.11.001, 2709458, 18083018.
45. Svenungsson E, Fei GZ, Jensen-Urstad K, de Faire U, Hamsten A, Frostegard J. TNF-alpha: a link between hypertriglyceridaemia and inflammation in SLE patients with cardiovascular disease. Lupus 2003, 12:454-461. 10.1191/0961203303lu412oa, 12873047.
46. Svenungsson E, Cederholm A, Jensen-Urstad K, Fei GZ, de Faire U, Frostegård J. Endothelial function and markers of endothelial activation in relation to cardiovascular disease in systemic lupus erythematosus. Scand J Rheumatol 2008, 37:352-359. 10.1080/03009740802007514, 18666029.
47. Major AS, Singh RR, Joyce S, Van Kaer L. The role of invariant natural killer T cells in lupus and atherogenesis. Immunol Res 2006, 34:49-66. 10.1385/IR:34:1:49, 2291524, 16720898.
48. Becker-Merok A, Eilertsen G, Nossent JC. Levels of transforming growth factor-β are low in systemic lupus erythematosus patients with active disease. J Rheumatol 2010, 37:2039-2045. 10.3899/jrheum.100180, 20682675.
49. van Es T, van Puijvelde GH, Ramos OH, Segers FM, Joosten LA, van den Berg WB, Michon IM, de Vos P, van Berkel TJ, Kuiper J. Attenuated atherosclerosis upon IL-17R signaling disruption in LDLr deficient mice. Biochem Biophys Res Commun 2009, 388:261-265. 10.1016/j.bbrc.2009.07.152, 19660432.
50. Mok MY, Wu HJ, Lo Y, Lau CS. The relation of interleukin 17 (IL-17) and IL-23 to Th1/Th2 cytokines and disease activity in systemic lupus erythematosus. J Rheumatol 2010, 37:2046-2052. 10.3899/jrheum.100293, 20682672.
51. Yang J, Chu Y, Yang X, Gao D, Zhu L, Yang X, Wan L, Li M. Th17 and natural Treg cell population dynamics in systemic lupus erythematosus. Arthritis Rheum 2009, 60:1472-1483. 10.1002/art.24499, 19404966.
52. Chung CP, Long AG, Solus JF, Rho YH, Oeser A, Raggi P, Stein CM. Adipocytokines in systemic lupus erythematosus: relationship to inflammation, insulin resistance and coronary atherosclerosis. Lupus 2009, 18:799-806. 10.1177/0961203309103582, 2707942, 19578104.
53. Clancy R, Ginzler E. Endothelial function and its implications for cardiovascular and renal disease in systemic lupus erythematosus. Rheum Dis Clin North Am 2010, 36:145-160. 10.1016/j.rdc.2009.12.011, 20202596.
54. Aprahamian T, Bonegio RG, Richez C, Yasuda K, Chiang LK, Sato K, Walsh K, Rifkin IR. The peroxisome proliferator-activated receptor {gamma} agonist rosiglitazone ameliorates murine lupus by induction of adiponectin. J Immunol 2009, 182:340-346. 2841959, 19109165.
55. Braun N, Wade N, Wakeland E, Major A. Accelerated atherosclerosis is independent of feeding high fat diet in systemic lupus erythematosus- susceptible LDLr-/- mice. Lupus 2008, 17:1070-1078. 10.1177/0961203308093551, 2662384, 19029274.
56. Kaplan MJ, Lewis EE, Shelden EA, Somers E, Pavlic R, McCune WJ, Richardson BC. The apoptotic ligands TRAIL, TWEAK, and Fas ligand mediate monocyte death induced by autologous lupus T cells. J Immunol 2002, 169:6020-6029.
57. Al-Lamki R, Bradley J, Pober J. Endothelial cells in allograft rejection. Transplantation 2008, 86:1340-1348. 10.1097/TP.0b013e3181891d8b, 2658756, 19034000.
58. Bonelli M, Smolen JS, Scheinecker C. Treg and lupus. Ann Rheum Dis 2010, 69:i65-i66. 10.1136/ard.2009.117135, 19995748.
59. Nilsson J, Wigren M, Shah P. Regulatory T cells and the control of modified lipoprotein autoimmunity-driven atherosclerosis. Trends Cardiovasc Med 2009, 19:272-276. 10.1016/j.tcm.2010.02.010, 20447570.
60. Wu G, Hu W, Shahsafaei A, Song W, Dobarro M, Sukhova GK, Bronson RR, Shi GP, Rother RP, Halperin JA, Qin X. Complement regulator CD59 protects against atherosclerosis by restricting the formation of complement membrane attack complex. Circ Res 2009, 104:550-558. 10.1161/CIRCRESAHA.108.191361, 19131645.
61. Clancy RM. Circulating endothelial cells and vascular injury in systemic lupus erythematosus. Curr Rheumatol Rep 2000, 2:39-43. 10.1007/s11926-996-0067-6, 11123038.
62. Bassi N, Zampieri S, Ghirardello A, Tonon M, Zen M, Beggio S, Matsuura E, Doria A. Oxldl/2gpi complex and anti-oxldl/2gpi In Sle: prevalence and correlates. Autoimmunity 2009, 42:289-291. 10.1080/08916930902828247, 19811279.
63. Fraser DA, Tenner AJ. Innate immune proteins C1q and mannan-binding lectin enhance clearance of atherogenic lipoproteins by human monocytes and macrophages. J Immunol 2010, 185:3932-3939. 10.4049/jimmunol.1002080, 20833838.
64. Haskard DO, Boyle JJ, Mason JC. The role of complement in atherosclerosis. Curr Opin Lipidol 2008, 19:478-482. 10.1097/MOL.0b013e32830f4a06, 18769228.
65. Mayadas TN, Tsokos GC, Tsuboi N. Mechanisms of immune complex-mediated neutrophil recruitment and tissue injury. Circulation 2009, 120:2012-2024. 10.1161/CIRCULATIONAHA.108.771170, 2782878, 19917895.
66. Borba EF, Bonf E, Vinagre CG, Ramires JA, Maranho RC. Chylomicron metabolism is markedly altered in systemic lupus erythematosus. Arthritis Rheum 2000, 43:1033-1040. 10.1002/1529-0131(200005)43:5<1033::AID-ANR11>3.0.CO;2-B, 10817556.
67. McMahon M, Grossman J, Skaggs B, Fitzgerald J, Sahakian L, Ragavendra N, Charles-Schoeman C, Watson K, Wong WK, Volkmann E, Chen W, Gorn A, Karpouzas G, Weisman M, Wallace DJ, Hahn BH. Dysfunctional proinflammatory high-density lipoproteins confer increased risk of atherosclerosis in women with systemic lupus erythematosus. Arthritis Rheum 2009, 60:2428-2437. 10.1002/art.24677, 2753974, 19644959.
68. Hahn BH, Lourencço EV, McMahon M, Skaggs B, Le E, Anderson M, Iikuni N, Lai CK, La Cava A. Pro-inflammatory high-density lipoproteins and atherosclerosis are induced in lupus-prone mice by a high-fat diet and leptin. Lupus 2010, 19:913-917. 10.1177/0961203310364397, 20410156.
69. Wang G, Pierangeli SS, Papalardo E, Ansari GA, Khan MF. Markers of oxidative and nitrosative stress in systemic lupus erythematosus: correlation with disease activity. Arthritis Rheum 2010, 62:2064-2072.
70. Ames PR, Margarita A, Delgado Alves J, Tommasino C, Iannaccone L, Brancaccio V. Anticardiolipin antibody titre and plasma homocysteine level independently predict intima media thickness of carotid arteries in subjects with idiopathic antiphospholipid antibodies. Lupus 2002, 11:208-214. 10.1191/0961203302lu165oa, 12043883.
71. Kiani AN, Magder L, Petri M. Coronary calcium in systemic lupus erythematosus is associated with traditional cardiovascular risk factors, but not with disease activity. J Rheumatol 2008, 35:1300-1306.
72. Delgado Alves J, Ames PR, Donohue S, Stanyer L, Nourooz-Zadeh J, Ravirajan C, Isenberg DA. Antibodies to high-density lipoprotein and beta2-glycoprotein I are inversely correlated with paraoxonase activity in systemic lupus erythematosus and primary antiphospholipid syndrome. Arthritis Rheum 2002, 46:2686-2694. 10.1002/art.10542, 12384928.
73. George J, Harats D, Gilburd B, Afek A, Levy Y, Schneiderman J, Barshack I, Kopolovic J, Shoenfeld Y. Immunolocalization of beta2-glycoprotein I (apolipoprotein H) to human atherosclerotic plaques: potential implications for lesion progression. Circulation 1999, 99:2227-2230.
74. Baron MA, Khamashta MA, Hughes GRV, D'Cruz DP. Prevalence of an abnormal ankle-brachial index in patients with primary antiphospholipid syndrome: preliminary data. Ann Rheuma Dis 2005, 64:144-146. 10.1136/ard.2003.016204, 1755181, 15608314.
75. Gresele P, Migliacci R, Vedovati MC, Ruffatti A, Becattini C, Facco M, Guglielmini G, Boscaro E, Mezzasoma AM, Momi S, Pengo V. Patients with primary antiphospholipid antibody syndrome and without associated vascular risk factors present a normal endothelial function. Thromb Res 2009, 123:444-451. 10.1016/j.thromres.2008.05.015, 18617225.
76. Farzaneh-Far A, Roman MJ, Lockshin MD, Devereux RB, Paget SA, Crow MK, Davis A, Sammaritano L, Levine DM, Salmon JE. Relationship of antiphospholipid antibodies to cardiovascular manifestations of systemic lupus erythematosus. Arthritis Rheum 2006, 54:3918-3925. 10.1002/art.22265, 17133599.
77. Sacré K, Brihaye B, Hyafil F, Serfaty JM, Escoubet B, Zennaro MC, Lidove O, Laissy JP, Papo T. Asymptomatic myocardial ischemic disease in antiphospholipid syndrome: a controlled cardiac magnetic resonance imaging study. Arthritis Rheum 2010, 62:2093-2100. 10.1002/art.27304, 20506512.
78. O'Neill SG, Giles I, Lambrianides A, Manson J, D'Cruz D, Schrieber L, March LM, Latchman DS, Isenberg DA, Rahman A. Antibodies to apolipoprotein A-I, high-density lipoprotein, and C-reactive protein are associated with disease activity in patients with systemic lupus erythematosus. Arthritis Rheum 2010, 62:845-854. 10.1002/art.27286, 20131231.
79. Rodrigues CEM, Bonfá E, Carvalho JF. Review on anti-lipoprotein lipase antibodies. Clin Chimi Acta 2010, 411:1603-1605. 10.1016/j.cca.2010.07.028, 20673827.
80. Domiciano D, Carvalho J, Shoenfeld Y. Pathogenic role of anti-endothelial cell antibodies in autoimmune rheumatic diseases. Lupus 2009, 18:1233-1238. 10.1177/0961203309346654, 19880574.
81. Duval A, Helley D, Capron L, Youinou P, Renaudineau Y, Dubucquoi S, Fischer AM, Hachulla E. Endothelial dysfunction in systemic lupus patients with low disease activity: evaluation by quantification and characterization of circulating endothelial microparticles, role of anti-endothelial cell antibodies. Rheumatology 2010, 49:1049-1055. 10.1093/rheumatology/keq041, 20211868.
82. Elliott J, Manzi S. Cardiovascular risk assessment and treatment in systemic lupus erythematosus. Best Pract Res Clin Rheumatol 2009, 23:481-494. 10.1016/j.berh.2009.03.005, 19591779.
83. Meyer O. Anti-CRP antibodies in systemic lupus erythematosus. Joint Bone Spine 2010, 77:384-389. 10.1016/j.jbspin.2010.04.010, 20627790.
84. George J, Harats D, Gilburd B, Levy Y, Langevitz P, Shoenfeld Y. Atherosclerosis-related markers in systemic lupus erythematosus patients: the role of humoral immunity in enhanced atherogenesis. Lupus 1999, 8:220-226. 10.1191/096120399678847597, 10342715.
85. Mandal K, Foteinos G, Jahangiri M, Xu Q. Role of antiheat shock protein 60 autoantibodies in atherosclerosis. Lupus 2005, 14:742-746. 10.1191/0961203305lu2212oa, 16218479.
86. Petri M. Hydroxychloroquine use in the Baltimore Lupus Cohort: effects on lipids, glucose and thrombosis. Lupus 1996, 5(Suppl 1):S16-22. 10.1177/096120339600500105, 8803905.
87. Roman MJ, Shanker BA, Davis A, Lockshin MD, Sammaritano L, Simantov R, Crow MK, Schwartz JE, Paget SA, Devereux RB, Salmon JE. Prevalence and correlates of accelerated atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2399-2406. 10.1056/NEJMoa035471, 14681505.
88. Selzer F, Sutton-Tyrrell K, Fitzgerald S, Tracy R, Kuller L, Manzi S. Vascular stiffness in women with systemic lupus erythematosus. Hypertension 2001, 37:1075-1082.
89. Asanuma Y, Oeser A, Shintani AK, Turner E, Olsen N, Fazio S, Linton MF, Raggi P, Stein CM. Premature coronary-artery atherosclerosis in systemic lupus erythematosus. N Engl J Med 2003, 349:2407-2415. 10.1056/NEJMoa035611, 14681506.
90. Shinjo SK, Bonfá E, Wojdyla D, Borba EF, Ramirez LA, Scherbarth HR, Brenol JC, Chacón-Diaz R, Neira OJ, Berbotto GA, De La Torre IG, Acevedo-Vázquez EM, Massardo L, Barile-Fabris LA, Caeiro F, Silveira LH, Sato EI, Buliubasich S, Alarcón GS, Pons-Estel BA, . Grupo Latino Americano de Estudio del Lupus Eritematoso (Gladel) Antimalarial treatment may have a time-dependent effect on lupus survival: data from a multinational Latin American inception cohort. Arthritis Rheum 2010, 62:855-862. 10.1002/art.27300, 20131238, Grupo Latino Americano de Estudio del Lupus Eritematoso (Gladel).
91. Kalia S, Dutz JP. New concepts in antimalarial use and mode of action in dermatology. Dermatol Ther 2007, 20:160-174. 10.1111/j.1529-8019.2007.00131.x, 17970883.
92. Gibson WT, Hayden MR. Mycophenolate mofetil and atherosclerosis: results of animal and human studies. Ann N Y Acad Sci 2007, 1110:209-221. 10.1196/annals.1423.023, 17911436.
93. van Leuven SI, van Wijk DF, Volger OL, de Vries JP, van der Loos CM, de Kleijn DV, Horrevoets AJ, Tak PP, van der Wal AC, de Boer OJ, Pasterkamp G, Hayden MR, Kastelein JJ, Stroes ES. Mycophenolate mofetil attenuates plaque inflammation in patients with symptomatic carotid artery stenosis. Atherosclerosis 2010, 211:231-236. 10.1016/j.atherosclerosis.2010.01.043, 20202636.
94. Mok CC, Poon WL, Lai JP, Wong CK, Chiu SM, Wong CK, Lun SW, Ko GT, Lam CW, Lam CS. Metabolic syndrome, endothelial injury, and subclinical Page 10 of 10 atherosclerosis in patients with systemic lupus erythematosus. Scand J Rheumatol 2010, 39:42-49. 10.3109/03009740903046668, 20132070.
95. Mosca M, Tani C, Aringer M, Bombardieri S, Boumpas D, Brey R, Cervera R, Doria A, Jayne D, Khamashta MA, Kuhn A, Gordon C, Petri M, Rekvig OP, Schneider M, Sherer Y, Shoenfeld Y, Smolen JS, Talarico R, Tincani A, van Vollenhoven RF, Ward MM, Werth VP, Carmona L. European League Against Rheumatism recommendations for monitoring patients with systemic lupus erythematosus in clinical practice and in observational studies. Ann Rheum Dis 2010, 69:1269-1274. 10.1136/ard.2009.117200, 19892750.
96. Wajed J, Ahmad Y, Durrington PN, Bruce IN. Prevention of cardiovascular disease in systemic lupus erythematosus - proposed guidelines for risk factor management. Rheumatology 2004, 43:7-12. 10.1093/rheumatology/keg436, 12867578.
97. Ferreira GA, Navarro TP, Telles RW, Andrade LEC, Sato EI. Atorvastatin therapy improves endothelial-dependent vasodilation in patients with systemic lupus erythematosus: an 8 weeks controlled trial. Rheumatology 2007, 46:1560-1565. 10.1093/rheumatology/kem186, 17693444.
98. Dimmeler S, Aicher A, Vasa M, Mildner-Rihm C, Adler K, Tiemann M, Rütten H, Fichtlscherer S, Martin H, Zeiher AM. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest 2001, 108:391-397. 209365, 11489932.
99. Petri M. Lupus Atherosclerosis Prevention Study (LAPS): a randomized double blind placebo controlled trial of atorvastatin versus placebo. Arthritis Rheum 2006, 54:S520.
100. Sandborg CI, Barnhart HX, Ardoin SP, Yow E, Evans GW, Mieszkalski KL, Ilowite NT, Eberhard A, Imundo LF, Kimura Y, Von Scheven E, Silverman E, Bowyer SL, Punaro L, Singer NG, Sherry DD, McCurdy D, Klein-Gittelman M, Wallace CA, Silver R, Wagner-Weiner L, Higgins GC, Brunner HI, Jung L, Soep JB, Reed A, Tegler C, . APPLE Investigators Does atorvastatin reduce progression of carotid intimal medial thickening in childhood SLE? Results from the Atherosclerosis Prevention in Pediatric Lupus (APPLE) trial: a multicenter, randomized, double-blind placebo-controlled study [abstract]. Arthritis Rheum 2010, 62:S1677. APPLE Investigators.
101. Aprahamian T, Bonegio R, Rizzo J, Perlman H, Lefer DJ, Rifkin IR, Walsh K. Simvastatin treatment ameliorates autoimmune disease associated with accelerated atherosclerosis in a murine lupus model. J Immunol 2006, 177:3028-3034. 2752011, 16920939.
102. Amuro H, Ito T, Miyamoto R, Sugimoto H, Torii Y, Son Y, Nakamichi N, Yamazaki C, Hoshino K, Kaisho T, Ozaki Y, Inaba M, Amakawa R, Fukuhara S. Statins, inhibitors of 3-hydroxy-3-methylglutaryl-coenzyme A reductase, function as inhibitors of cellular and molecular components involved in type I interferon production. Arthritis Rheum 2010, 62:2073-2085.
103. Lin BF, Jeng SJ, Chiang BL, Huang CC. Dietary fat affects lipids and anti-cardiolipin antibody levels in autoimmune-prone NZB/W F1 mice. Br J Nutr 1997, 77:657-669. 10.1079/BJN19970063, 9155512.